Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Olaf Bergmann,1*Ratan D. Bhardwaj,1*Samuel Bernard,2Sofia Zdunek,1Fanie Barnabé-Heider,1Stuart Walsh,3Joel Zupicich,1Kanar Alkass,4Bruce A. Buchholz,5Henrik Druid,4Stefan Jovinge,3,6Jonas Frisén1
It has been difficult to establish whether we are limited tothe heart muscle cells we are born with or if cardiomyocytesare generated also later in life. We have taken advantage ofthe integration of carbon-14, generated by nuclear bomb testsduring the Cold War, into DNA to establish the age of cardiomyocytesin humans. We report that cardiomyocytes renew, with a gradualdecrease from 1% turning over annually at the age of 25 to 0.45%at the age of 75. Fewer than 50% of cardiomyocytes are exchangedduring a normal life span. The capacity to generate cardiomyocytesin the adult human heart suggests that it may be rational towork toward the development of therapeutic strategies aimedat stimulating this process in cardiac pathologies.
1 Department of Cell and Molecular Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden. 2 CNRS UMR5208, Institut Camille Jordan, Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France. 3 Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, SE-221 84 Lund, Sweden. 4 Department of Forensic Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden. 5 Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, 7000 East Avenue, L-397, Livermore, CA 94551, USA. 6 Department of Cardiology, Lund University Hospital, SE-221 85 Lund, Sweden.
* These authors contributed equally to this work.
To whom correspondence should be addressed. E-mail: jonas.frisen{at}ki.se
Charles E. Murry and Richard T. Lee (3 April 2009) Science324 (5923), 47.
[DOI: 10.1126/science.1172255] |Summary »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Clonality of mouse and human cardiomyogenesis in vivo.
T. Hosoda, D. D'Amario, M. C. Cabral-Da-Silva, H. Zheng, M. E. Padin-Iruegas, B. Ogorek, J. Ferreira-Martins, S. Yasuzawa-Amano, K. Amano, N. Ide-Iwata, et al. (2009)
PNAS
106, 17169-17174
|Abstract »|Full Text »|PDF »
Diurnal physiology: core principles with application to the pathogenesis, diagnosis, prevention, and treatment of myocardial hypertrophy and failure.
Cardiac Cell Repair Therapy: A Clinical Perspective.
B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic (2009)
Mayo Clin. Proc.
84, 876-892
|Abstract »|Full Text »|PDF »
Optimizing Cell-Based Therapy for Cardiac Regeneration.
D. P. Del Re and J. Sadoshima (2009)
Circulation
120, 831-834
|Full Text »|PDF »
Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency.
B. G. Galvez, D. Covarello, R. Tolorenzi, S. Brunelli, A. Dellavalle, S. Crippa, S. A. A. Mohammed, L. Scialla, I. Cuccovillo, F. Molla, et al. (2009)
Cardiovasc Res
83, 707-716
|Abstract »|Full Text »|PDF »
c-kit cardiac progenitor cells: What is their potential?.
I. Chimenti, R. Gaetani, L. Barile, G. Frati, E. Messina, and A. Giacomello (2009)
PNAS
106, E78
|Full Text »|PDF »
Cardiomyocyte Renewal.
M. S. Parmacek and J. A. Epstein (2009)
N. Engl. J. Med.
361, 86-88
|Full Text »|PDF »
Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease.